These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 10701701)
1. Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. Everett DW; Franz TJ; Chando TJ; Gale PJ; Lehman PA; Schwarzel EH; Parab PV; D'Arienzo CJ; Kripalani KJ Biopharm Drug Dispos; 1999 Sep; 20(6):301-8. PubMed ID: 10701701 [TBL] [Abstract][Full Text] [Related]
2. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. Fleischer AB; Schwartzel EH; Colby SI; Altman DJ J Am Acad Dermatol; 2000 Mar; 42(3):459-67. PubMed ID: 10688717 [TBL] [Abstract][Full Text] [Related]
3. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. Draelos ZD J Cosmet Dermatol; 2006 Sep; 5(3):239-44. PubMed ID: 17177746 [TBL] [Abstract][Full Text] [Related]
4. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Jarratt M Cutis; 2004 Nov; 74(5):319-22. PubMed ID: 15605971 [TBL] [Abstract][Full Text] [Related]
5. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. Latriano L; Tzimas G; Wong F; Wills RJ J Am Acad Dermatol; 1997 Mar; 36(3 Pt 2):S37-46. PubMed ID: 9091507 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. Ortonne JP; Camacho F; Wainwright N; Bergfelt L; Westerhof W; Roseeuw D Cutis; 2004 Oct; 74(4):261-4. PubMed ID: 15551721 [TBL] [Abstract][Full Text] [Related]
7. Absorption of tretinoin in rats and rabbits following oral and dermal application. Chou R; Bürgin H; Schmitt G; Eggers H Arzneimittelforschung; 1997 Apr; 47(4):401-5. PubMed ID: 9150861 [TBL] [Abstract][Full Text] [Related]
8. Are topical retinoids teratogenic? Veraldi S; Rossi LC; Barbareschi M G Ital Dermatol Venereol; 2016 Dec; 151(6):700-705. PubMed ID: 27598619 [TBL] [Abstract][Full Text] [Related]
9. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Keeling J; Cardona L; Benitez A; Epstein R; Rendon M Cutis; 2008 Feb; 81(2):179-83. PubMed ID: 18441773 [TBL] [Abstract][Full Text] [Related]
10. Analytic quantification of the bleaching effect of a 4-hydroxyanisole-tretinoin combination on actinic lentigines. Piérard-Franchimont C; Henry F; Quatresooz P; Vroome V; Piérard GE J Drugs Dermatol; 2008 Sep; 7(9):873-8. PubMed ID: 19112802 [TBL] [Abstract][Full Text] [Related]
12. Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man. van Hoogdalem EJ; Baven TL; Spiegel-Melsen I; Terpstra IJ Biopharm Drug Dispos; 1998 Dec; 19(9):563-9. PubMed ID: 9872337 [TBL] [Abstract][Full Text] [Related]
13. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 5th communication: factors affecting percutaneous absorption in rats. Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Okamura Y; Kashiwazaki K; Takahashi N Arzneimittelforschung; 1997 Mar; 47(3):270-5. PubMed ID: 9105545 [TBL] [Abstract][Full Text] [Related]
14. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347 [TBL] [Abstract][Full Text] [Related]
15. Percutaneous absorption, excretion and metabolism of all-trans-retinoyl beta-glucuronide and of all-trans-retinoic acid in the rat. Barua AB; Olson JA Skin Pharmacol; 1996; 9(1):17-26. PubMed ID: 8868029 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design. Saghir SA; Clark AJ; McClymont EL; Staley JL Food Chem Toxicol; 2008 Feb; 46(2):678-87. PubMed ID: 17961896 [TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. Le Doze F; Debruyne D; Albessard F; Barre L; Defer GL Drug Metab Dispos; 2000 Feb; 28(2):205-8. PubMed ID: 10640519 [TBL] [Abstract][Full Text] [Related]
19. Repeated topical administration of all-trans-retinoic acid and plasma levels of retinoic acids in humans. Buchan P; Eckhoff C; Caron D; Nau H; Shroot B; Schaefer H J Am Acad Dermatol; 1994 Mar; 30(3):428-34. PubMed ID: 8113456 [TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Muindi JR; Frankel SR; Huselton C; DeGrazia F; Garland WA; Young CW; Warrell RP Cancer Res; 1992 Apr; 52(8):2138-42. PubMed ID: 1559217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]